Killing projects, drug discovery and career progression

Updated: Jul 26

Season 02: episode 18

In this episode of the podcast, the GOLD team is joined by Eric Bouilloux, Chief Development Officer, Istesso – a drug discovery and development company working within the field of immunometabolism. The team also covers the recent FDA approval of GSK's measles, mumps and rubella vaccine Priorix in 'Thing's you might have missed'.

In this week's interview, Helena asks Eric about his impressive career within the pharmaceutical space, the potential of immunometabolism in diseases like multiple sclerosis, tips and tricks for progressing within a chosen career path and to review his predictions from his first interview with GOLD in 2019.


A little more on GOLD’s guest…


Eric Bouilloux started his pharmaceutical career in 1996 in clinical research, before moving to Ipsen as a Global Project Leader in 2001. Since then, his career has taken him to many different pharma companies and functions, with his roles ranging from management and drug development to product development in fields including oncology, gastro-enterology, bone health, inflammation, CNS and neurosciences. More recently, Eric became Chief Development Officer at Istesso, a company with a clinical development pipeline of immunometabolism drugs that reprogramme metabolism in target immune cells, offering novel treatments for various autoimmune conditions.

Additional resources


If you’re interested in learning more about the topic areas discussed in this episode, check out the following content:

Click here to subscribe to the weekly newsletter for more insights from GOLD.